Neurotransmitter-Mimicking Nanovesicles Facilitate Postoperative Glioblastoma Stem Cell-Specific Treatment for Preventing Tumor Recurrence.

in Advanced science (Weinheim, Baden-Wurttemberg, Germany) by Fuming Liang, Qing You, Bin Yu, Chen Wang, Yanlian Yang, Ling Zhu, Zhaohui He

TLDR

  • Researchers developed a neurotransmitter-mimicking nanovesicle (PMVS-P) to target and kill glioblastoma stem cells (GSCs) at the surgical incision, suppressing tumor recurrence.

Abstract

Survival quality of glioblastoma (GBM) patients remains undesirable despite the aggressive multimodal treatment methods implemented, which are strongly associated with tumor recurrence after surgical resection. Self-renewal and strong tumourigenic capacity of glioblastoma stem cells (GSCs) at the narrow margin of the incision are essential factors driving tumor secondary strikes. Currently, the challenges in treating postoperative residual GSCs are mainly due to the lack of materials for incision and GSCs targeting. In this study, a neurotransmitter-mimicking nanovesicle (PMVS-P) based on platelet membrane-derived vesicle (PMV) with anti-GSC drug salinomycin (SAL)-loading and polydopamine (PDA)-surface is synthesized. PMVS-P exhibits surgical incision targeting ability and specifically identified GSCs with highly expressed D2 dopamine receptor (D2DR), a central nervous system neurotransmitter receptor, thus suppressing GBM recurrence. This neurotransmitter-mimicking nanovesicle primed GSC-specific tumoricidal treatment with broadened applications for preventing tumor recurrence.

Overview

  • The study aims to investigate the treatment of postoperative residual glioblastoma stem cells (GSCs) to prevent tumor recurrence.
  • The researchers developed a neurotransmitter-mimicking nanovesicle (PMVS-P) loaded with anti-GSC drug salinomycin (SAL) to target GSCs at the surgical incision.
  • The primary objective is to explore the application of PMVS-P for suppressing glioblastoma recurrence after surgical resection.

Comparative Analysis & Findings

  • PMVS-P exhibited surgical incision targeting ability and specifically identified GSCs with highly expressed D2 dopamine receptor (D2DR).
  • The neurotransmitter-mimicking nanovesicle primed GSC-specific tumoricidal treatment, suppressing GBM recurrence.
  • The study highlights the potential of PMVS-P for preventing tumor recurrence, offering a novel and targeted therapeutic approach for glioblastoma treatment.

Implications and Future Directions

  • The findings of this study suggest that PMVS-P has broad applications for preventing tumor recurrence and warrants further investigation in clinical trials.
  • Future research directions may involve optimizing the composition of PMVS-P and exploring its use in combination with other therapeutic agents.
  • The study's results also highlight the importance of understanding the role of GSCs in glioblastoma recurrence and developing targeted therapies for this population.
Read Full Article